Beijing University of Chinese Medicine, Beijing, 100102, China.
State Key Laboratory of Generic Manufacture Technology of Chinese Traditional Medicine, Linyi, 276000, China.
Sci Rep. 2020 Jul 10;10(1):11448. doi: 10.1038/s41598-020-68224-7.
Yinzhihuang granules (YZHG) is a patented Chinese medicine for the treatment of hepatitis B. This study aimed to investigate the intrinsic mechanisms of YZHG in the treatment of hepatitis B and to provide new evidence and insights for its clinical application. The chemical compounds of YZHG were searched in the CNKI and PUBMED databases, and their putative targets were then predicted through a search of the SuperPred and Swiss Target Prediction databases. In addition, the targets of hepatitis B were obtained from TTD, PharmGKB and DisGeNET. The abovementioned data were visualized using Cytoscape 3.7.1, and network construction identified a total of 13 potential targets of YZHG in the treatment of hepatitis B. Molecular docking verification showed that CDK6, CDK2, TP53 and BRCA1 might be strongly correlated with hepatitis B treatment. Furthermore, GO and KEGG analyses indicated that the treatment of hepatitis B by YZHG might be related to positive regulation of transcription, positive regulation of gene expression, the hepatitis B pathway and the viral carcinogenesis pathway. Network pharmacology intuitively shows the multicomponent, multitarget and multichannel pharmacological effects of YZHG in the treatment of hepatitis B and provides a scientific basis for its mechanism of action.
茵栀黄颗粒（YZHG）是一种治疗乙型肝炎的专利中药。本研究旨在探讨 YZHG 治疗乙型肝炎的内在机制，为其临床应用提供新的证据和思路。在 CNKI 和 PUBMED 数据库中搜索 YZHG 的化学化合物，并通过 SuperPred 和 Swiss Target Prediction 数据库搜索预测其潜在靶点。此外，从 TTD、PharmGKB 和 DisGeNET 获得乙型肝炎的靶点。使用 Cytoscape 3.7.1 可视化上述数据，并通过网络构建确定了 YZHG 治疗乙型肝炎的 13 个潜在靶点。分子对接验证表明，CDK6、CDK2、TP53 和 BRCA1 可能与乙型肝炎的治疗密切相关。此外，GO 和 KEGG 分析表明，YZHG 治疗乙型肝炎可能与转录的正调控、基因表达的正调控、乙型肝炎途径和病毒致癌途径有关。网络药理学直观地显示了 YZHG 治疗乙型肝炎的多成分、多靶点和多途径的药理作用，为其作用机制提供了科学依据。
Zotero 插件
